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1. Introduction 9 
1.1 Conventional antibodies 10 
Recombinant antibodies are widely regarded as one of the main, if not the most promising 11 
tools against cancer and auto-immune, inflammatory, neurodegenerative and infectious 12 
diseases (Stiehm et al., 2008). Conventional antibodies (Abs) are complex molecules 13 
consisting of pairs of heavy and light chains, whose N- terminal domain is more variable 14 
than the rest of the protein sequence. The antibody heavy chain consists of three constant 15 
domains (CH1, CH2 and CH3) and a variable domain (VH). The light chain has only two 16 
domains, the constant light (CL) and the variable light (VL). Important Glycosylations on 17 
the CH2 domain are necessary for antibody effector functions, such as Antibody-Dependent 18 
Cellular Cytotoxicity (ADCC) and Complement–Dependent Cytolysis (CDC), and for 19 
regulating antibody half time in serum (Fig. 1, A). Antigen-binding is determined by the 20 
three hypervariable Complementary Determining Regions (CDR1, CDR2 and CDR3) 21 
present in both the VH and VL domains. These regions are located in juxtaposed loops, 22 
creating a continuous surface of ~ 1000 Å2 that specifically binds to the epitope in an 23 
antigen. Although all CDRs can potentially make contact with the antigen, CDR3 contacts 24 
with the epitope are generally more extensive. The structural diversity of the antigen-25 
binding sites of a conventional antibody depends on the size of the CDR3 in the VH and the 26 
conjunction with the VL at different angles and distances. These are grouped in three 27 
different classes, according to the size and type of an antigen: cavities (fitting haptens), 28 
grooves (fitting peptides) and planar sites (fitting surface patches of proteins) (Johnson et al., 29 
2010). 30 
1.2 The single variable domain of the heavy chain antibodies 31 
In 1993 a surprising observation was made in members of the Artiodactyl Tylopoda family 32 
(camelids). Next to conventional IgG antibodies, camelids also naturally produce Heavy 33 
Chain antibodies (HCAbs) that lack the light chain (Hamers-Casterman et al., 1993). Two 34 
years later, similar single chain antibodies were discovered in cartilaginous fish (sharks) 35 
(Greenberg et al., 1995). Although the CH2 and CH3 of the HCAbs and the conventional 36 
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antibodies are highly homologous, there is no CH1 domain in the camelid HCAbs. The 1 
single variable domain, called VHH, is the only domain of HCAbs that makes contact with 2 
the antigen. Surprisingly, although the VHH have only three CDR regions, their affinity for 3 
antigens reaches the low nanomolar to even picomolar range, matching the best affinities of 4 
classical antibodies. When expressed as single domains (often referred to as nanobodies, Nb), 5 
the VHHs retain their strong epitope specificity and affinity, a feature that might be 6 
explained by the VHH architecture (Fig. 1, B). Just like the VHs of conventional antibodies, 7 
the amino acid (AA) sequence of VHHs is organised in three hypervariable regions (CDR1, 8 
CDR2 and CDR3) separated by four Framework regions (FR1-FR4) (Muyldermans et al., 9 
 10 
Fig. 1. Representative diagrams of a conventional antibody, an HCAb, and a VHH. (A) A 11 
conventional antibody is a dimeric molecule, and each monomer comprising a heavy chain 12 
and a light chain. The heavy chain consists of the constant domains (CH1, CH2 and CH3) 13 
and the variable domain (VH). The light chain has only one conserved domain (CL) and a 14 
variable domain (VL). Important glycosylation sites (orange stars) are present in CH2, which 15 
is responsible for effector functions and the flexibility of the molecule. (B) The HCAb devoid 16 
of the light chain and CH1 is the paratope (yellow box) present only in the single variable 17 
domain (VHH). (C) The VHH can be expressed as a prolate-shaped, soluble molecule of ~15 18 
kDa. The yellow square shows the antigen binding site. (D) The VHH sequence is made of 19 
four Framework Regions (FR1, light gray; FR2, cyan; FR3, magenta and FR4, yellow), and 20 
three Complementary Determining Regions (CDR1, green; CDR2, blue and CDR3, red). 21 
Residues F37, E44, G47and R45 (orange) are located in the FR2 and mask a hydrophobic 22 
patch. C, C- terminal; N, N-terminal. The dotted red line represents a disulfide bond 23 
between the FR2 and the CDR3; this bond stabilizes the molecule and is present in 24 
dromedaries. (E) A three-dimensional structure of an anti lysozyme VHH, showing the Ig 25 
folding of β sheets, five strands in the front (roman numerals: I – V) and four strands in the 26 
back (VI – IX). The enlarged yellow square shows the antigen binding site, formed by 27 
juxtaposition of three CDRs. (F) The VHH shown in (F) is drawn in complex with lysozyme 28 
(light blue). A protruding paratope consisting mainly of CDR3 (red) recognizes and binds 29 
the catalytic cleft of lysozyme, inhibiting its activity. 30 
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1994). As the AA sequence of the VHH FRs is highly similar to those of conventional VHs it 1 
was not surprising that the overall architecture of VHHs closely resembles that of VHs 2 
(Muyldermans et al., 1994). Both VHH and VH domains fold  into two β-sheets with the 3 
three CDRs that link these two sheets at one end of the barrel (or domain) (De Genst et al., 4 
2006; Desmyter et al., 1996) (Fig. 1, C,E).  However, there are striking structural differences 5 
between VHHs and conventional VH. Evidently, VHHs lack an interacting VL domain. 6 
Associated with this lack, the hydrophobic amino acids present at the VH surface that is 7 
normally interacting with the VL, are substituted by hydrophilic AA (Fig.1, D). This 8 
enhances the solubility of VHH single domain proteins compared to engineered VH single 9 
domain proteins.  10 
The absence of the additional CDRs in VHHs is likely compensated by structural features. 11 
First, the CDR3 regions of camelid VHHs are generally longer (13-17 amino acids) than the 12 
CDR3 regions of mouse and human VHs (9-12 and 9-17 AA respectively) (Wu et al., 1993). In 13 
contrast to conventional Abs, in which the antigen binding surface is often a flat surface, a 14 
cavity or a groove, the long CDR3 loop may extend from the antigen binding surface 15 
(Desmyter et al., 1996). This enlarges the paratope surface and hence the potential affinity 16 
and repertoire of camelid HCAbs. In addition, especially in dromedaries, the CDR1 and 17 
CDR3 regions contain a cysteine, which allows formation of a second disulfide bridge next 18 
to the single disulfide bridge in conventional VHs (Muyldermans et al., 1994). This extra 19 
bridge likely stabilizes the CDR loops, thereby reducing their flexibility. This probably also 20 
contributes to the affinity (less entropy is lost upon antigen binding) and structural diversity 21 
of VHHs.  Long extending CDR3 loops that are stabilized by an extra disulfide bridge can 22 
explain the tendency of VHHs to bind to clefts and concaves surfaces more readily than 23 
conventional antibodies do (Fig.  1, F) (De Genst et al., 2006). Indeed comparison of multiple 24 
structures of hen egg white lysozyme interacting with either several conventional human 25 
antibodies or several camelid VHHs clearly illustrated that VHHs tends to bind to the 26 
concave substrate-binding pocket, whereas conventional antibodies favor epitopes on the 27 
“flat” surface of the antigen (Fig. 1, C). In addition, whereas each of the three CDRs of 28 
conventional VHs contributes considerably to the interaction with antigen, VHHs depended 29 
mainly on the CDR 3 loop for this interaction. Other antigens that are hard to target by 30 
conventional antibodies, but can be targeted by cameloid VHHs are ion channels, GPCRs, 31 
haptens and enzymatic sites (Lauwereys et al., 1998) (Rasmussen et al., 2011). 32 
Next to an extended CDR3, the AA sequence of the H1 loop that precedes and comprises 33 
CDR1 appears to be particularly more variable in camelid VHHs than in conventional VHs. 34 
This might be interpreted as an extension of the VHH CDR1 (Vu et al., 1997). Associated 35 
with this high variability in camelid VHHs, CH1 loops adopt conformations that deviate 36 
from the canonical H1 structures of conventional VHs (Barre et al., 1994); (Decanniere et al., 37 
1999; Decanniere et al., 2000). Camelid VHH CH1 loops appear to fold into a more diverse 38 
repertoire of structures. The high variability in the AA sequence and conformations of the 39 
CH1 loop contribute to the VHH paratope size (850-1150 Å2), which approaches that of 40 
conventional antibodies (VH + VL) (Desmyter et al., 2002). Clearly, different biochemical 41 
and structural features of camelid VHHs compensate for the lack of a VL domain and 42 
allowing a broad repertoire of specific high affinity antigen interactions. In addition, due to 43 
their small size and typical extruding CDR3 regions, camelid VHH tend to bind in cavities 44 
that are not readily accessible for conventional antibodies. Next to these particular features, 45 
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VHH single domain protein is exceptionally stable and soluble, even in stringent conditions. 1 
As VHH are small and naturally monomeric, they can be easily formatted. In addition, the 2 
small size of VHHs allows them penetrate deeper into tissue (e.g. tumor tissue) and to 3 
occasionally cross the blood-brain barrier. On the down side, the small size of single domain 4 
VHH contributes to their rapid clearance from circulation. 5 
Using display technologies, it is possible to select VHHs from large, synthetic or naive 6 
libraries (Verheesen et al., 2006). Nevertheless, the phage display generated from an immune 7 
VHH repertoire is the most widely and powerful technique used nowadays to rapidly select 8 
VHHs with the desired specificity (Arbabi Ghahroudi et al., 1997). VHH are easily produced 9 
in bacterial or yeast systems in miligram quantities per liter of culture. Their stability, 10 
solubility, ease of production and small size make them excellent candidates for multivalent 11 
formatting. Tailor-made constructions using VHHs as building blocks enhance the avidity of 12 
the molecule even in a 3 log scale, and several constructions are being tested in clinical trials 13 
(Els Conrath et al., 2001; Hmila et al., 2010). Their high potential as therapeutics had 14 
prompted the creation in Belgium of the company Ablynx in 2001. Because of the publicity 15 
surrounding nanotechnology and the small size of the VHH, Ablynx named the VHH as 16 
“Nanobody (Nb)”, and retains full intellectual property rights of the use of Nbs in 17 
therapeutics and diagnosis. The combined features of VHHs potential tools for many 18 
applications. In this chapter, we focus on the development and use of VHHs for anti-viral 19 
therapy. It is interesting to point that in the field of therapy, only one monoclonal antibody 20 
is used today (Synagis) against infectious disease (Groothuis & Simoes, 1993). 21 
2. Influenza virus 22 
Nowadays, the main prophylactic measure against  influenza is vaccination. Therapeutic 23 
options for influenza are small molecule drugs targeting the viral proteins Neuraminidase 24 
(NA) or matrix protein 2 (M2).  influenza virus poses a great and continuous threat to 25 
humans and zoonotic infections also pose a dangerous challenge to human. In the last six 26 
years, two important viruses have risen as pandemic or potential pandemic outbreaks: the 27 
recent pandemic outbreak in the 2009 by the swine-derived H1N1 influenza virus (also 28 
called the Mexican Flu) and Highly Pathogenic Avian  influenza (HPAV) viruses of the 29 
H5N1 subtype, mainly in Asiatic countries. The 2009 H1N1 pandemic presents an 30 
interesting case. It was a zoonotic infection that could be transmitted between humans, but 31 
had a low mortality rate. On the other hand, the HPAV H5N1 virus infections present a high 32 
replication efficiency, broader cell tropism and possible systemic spread in patients. 33 
Fulminant pneumonia, multi-organ failure caused by a high viral load and an intense 34 
inflammatory response (cytokine storm) are responsible of a mortality rate of 60 % (de Jong 35 
et al., 2006).  Vaccines to prevent HPAV infection are not available, but NA inhibitors 36 
(osetalmivir) are used as antiviral drugs. A combination of antiviral drugs and 37 
immunomodulators was used to control infection by HPAV H5N1 in patients, but its use 38 
was considered as a risk. On the other hand, passive immunization has been a successful 39 
alternative. Immunoglobulins in immune sera derived from animals or humans exposed to a 40 
homologous virus had been used to treat HPAV-infected humans (Luke & Subbarao, 2006; 41 
Zhou et al., 2007).  In addition, the genetic shift and drift of the influenza virus underline the 42 
need for new antiviral approaches. In addition, the emergence of drug resistant strains poses 43 
an extra concern. The Tamiflu Resistant strain (conferred mainly by the H274Y mutation, 44 
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Wang et al., 2002) is evidence of the urgent need of new anti-influenza tools. It is also urgent 1 
to develop new and better antiviral tools against the zoonotic  influenza virus, including 2 
HPAV. The characteristics of Nbs mentioned above makes them a potentially effective 3 
antiviral approach. Several attempts have been made to target conserved epitopes of 4 
proteins in the capsid of  influenza viruses. The main antigenic target in  influenza virus is 5 
the HA protein. However, the genetic shift of this viral protein, especially in its antigenic 6 
regions and including the binding site, complicates this approach. Even though this strategy 7 
has been successful in current seasonal vaccines, it is a costly and far from optimal: it is not 8 
suitable for emerging pandemic viruses, as has been proven not suitable by the Mexican flu 9 
in 2009.  10 
2.1 Targeting influenza HA: the Nb approach 11 
The work of Hultberg and colleagues (Hultberg et al., 2011) is the first report of the use of 12 
Nb technology as an antiviral tool against influenza. That study proved the binding of Nbs 13 
to an  influenza protein and the neutralization of the binding of the virion to its cellular 14 
receptor in human transformed mammalian cells. These results are the proof of principle of 15 
the use of Nbs as antivirals. We discuss the most relevant results in scope of the potential 16 
further use of Nbs. To obtain Nanobodies directed against H5N1 viruses, llamas were 17 
immunized with recombinant H5N1 Hemaglutinin (H5, A/Vietnam/1203/2004). The 18 
nanobody repertoire of the hyperimmune animals was cloned into a phage display library, 19 
and two promising HA-binding VHHs were isolated. The VHH of the HCab or Nb was 20 
cloned, produced as monovalent molecules, purified and screened for specific binding to the 21 
antigen, using as competitor the HA surrogate receptor fetuin. Two of the specific binders 22 
(B12 and C8) had high affinity to HA (KD = 9.91 and 30.1 nM) as determined by surface 23 
plasmon resonance. In addition, in a MLV (H5) pseudotyped neutralization assay both Nbs 24 
neutralized the parental virus A/Vietnam/1203/04 and also another clade 1 virus 25 
(A/Vietnam/1194/04) with a minimal inhibition concentration (IC50) of 75 nM. The 26 
possibility of cross reactivity among different H5N1 clades was also tested. The Nbs 27 
efficiency in neutralizing other clades of  influenza virus decreased proportionally with the 28 
antigenic distance from the virus A/Vietnam/1203/04. Three viruses from clade 2.2 were 29 
inhibited by the monovalent Nbs in a similar range as clade 1 (IC50 = 50–150 nM). On the 30 
other hand, one virus of clade 2.3.4 and one virus from clade 2.5 showed little or no 31 
inhibition. As mentioned above, Nbs are potentially good building blocks for multivalent 32 
molecules due their small size, high affinity, and efficacy as a production platform. Bivalent 33 
and trivalent constructs were made, based on the C-8, using Gly4/Ser linkers (GS) of 34 
different lengths. As expected, the neutralization potential of the bivalent and trivalent 35 
constructions was greatly enhanced against the A/Vietnam/1194/04 virus (IC50 ≤ 1 pM). 36 
Inhibition of this clade 1 virus was confirmed by a micronetralization assay in NIBRG-14 37 
infected cells. NIBRG-14 is an engineered recombinant virus whose HA and NA are derived 38 
from the A/Vietnam/1194/04 virus. Surprisingly, in the bivalent and trivalent Nbs the IC50 39 
neutralization activity (9 and 3 pM, respectively) decreased by more than 3 logs, compared 40 
to the monovalent Nb. These results show that the multimeric molecules outperformed a 41 
previously developed monoclonal antibody CR 261, against NIBRG-14 (Throsby et al., 2008). 42 
These results were also confirmed in a hemagglutination inhibition assay, which showed an 43 
IC50 of 2 nM for the bivalent and trivalent construction, compared to 156 nm of the 44 
monovalent. 45 
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The multivalency format also resulted in the potential for neutralization of  influenza virus 1 
of different clades. For three clade 2.2 viruses, two bivalent constructions of the Nb C-8 (9 2 
GS and 15 GS) did not show any decrease in the IC50. On the other hand, the 10 GS linker 3 
trivalent molecule showed a 10 - 40-fold increase in the neutralization potential, but the 20 4 
GS linker trivalent showed only two-fold decrease in the IC50, or none at all.  Nevertheless, 5 
using the monovalent Nb the neutralization of virus from clades 2.3.4 or 2.5 was in the high 6 
nM range or absent, respectively. This result confirms the previous result showing that both 7 
bivalent and one trivalent (10GS) constructions decrease the IC50 to a low nM range. It is 8 
worth mentioning that the retroviral pseudovirus A/Vietnam/1194/04 and the  influenza 9 
virus NIBRG-14 share the same HA, but different results were obtained using the MLV 10 
pseudotyped neutralization assay and the infected cells microneutralization. Using the 11 
microneutralization, the reported IC50 of the monovalent; bivalent and trivalent molecules 12 
was reduced by ten-fold compared to the IC50 obtained by the pseudotyped neutralization. 13 
The difference in sensitivity of the assays emphasizes the need to confirm the neutralization 14 
results of the different influenza clades in infected cells based assays. The validation of the 15 
anti HA in an in vivo model was performed in a mouse model by Ibañez (Ibañez et al., 2011). 16 
To confirm the in vivo efficacy of the Nbs, Ibañez and colleagues used an H5N1 NIBRG-14 17 
mouse adapted virus strain (NIBRG-14 ma). It is important to point out that the Nbs were 18 
administered intranasally in all mouse experiments, in order to enhance penetration in the 19 
respiratory tract. Initially, to evaluate the antiviral potential using the bivalent Nb (C-8, 15 20 
GS) in vivo, a dose of 5 mg/kg (100 µg) was used in mice. This dose completely prevented 21 
loss of body weight at 4, 24 and 48 h before a challenge of 1 LD50 of NIBRG-14 ma, compared 22 
to the controls after 4 days of monitoring. Using the same set up, on day 4 after challenge, 23 
any detectable lung virus titers were observed at 4 and 24 hrs before challenge, and at 48 hrs 24 
the titer was 50-fold lower than in controls. These results suggested that the bivalent Nb 25 
provide strong protection against 1 LD50, but it is important to consider the half life of the 26 
molecule. In previous in vitro results, the bivalent Nb neutralization activity was even 3 logs 27 
higher than that of the monovalent Nb, but in vivo also there was a significant improvement 28 
using the bivalent. The difference in the virus neutralization capacity between the 29 
monovalent and bivalent Nbs and the minimal protective dose was assessed by 30 
administration of Nbs at different doses at 24 h before challenge with 1 LD50 NIBRG-14. The 31 
doses of Nbs ranged from 3 to 0.025 mg/kg, and complete neutralization was confirmed for 32 
the highest doses of both constructions. In addition, administration of the highest dose (60 33 
µg, 3 mg/kg) of bivalent Nb 24 h before challenge with 4 LD50 also resulted in complete 34 
protection. The monovalent neutralization activity was dependent on the amount of Nb, but 35 
it was statistically also significant for doses of 6 or 1.2 µg of Nb per mouse. Remarkably, 36 
very low or any lung virus titer was detected in mice treated with the bivalent Nb, even for 37 
the lowest doses used (2.5–0.5 µg). These results strongly confirmed the neutralization 38 
efficacy of the bivalent Nb when used as prophylactic tool against a NIBRG-14 ma, a highly 39 
pathogenic  influenza virus model. 40 
In addition, the therapeutic efficacy of the bivalent Nb was also tested in the same model. 41 
The administration of 60 µg of bivalent Nb prevented the drop in body weight and showed 42 
a reduction in the lung viral titers when administered 4, 24 and 48 h after 1 LD50 challenge. 43 
On the other hand, 72 h after challenge, the drop in body weight was similar to that of the 44 
controls, but statistically significant reduction in lung viral titers was observed. The decrease 45 
in viral titers was also confirmed by measuring the amount of viral RNA by RT-PCR. In 46 
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addition, 48 h after challenge of mice (treated with this dose of bivalent Nb) with 4 LD50 of 1 
NIBRG-14 ma, weight loss was observed and also a delay in mortality compared with the 2 
controls.  3 
The antigenic site of the HA was mapped by escape mutants in presence of the monovalent 4 
or bivalent Nb. Three escape mutants were  selected in the presence of monovalent Nb, 5 
K189E/N and N154D/S mutations were found, they are contiguous in the antigenic B site of 6 
the HA (Wiley et al., 1981; Yamada et al., 2006). It is noteworthy to mention that N154D/S 7 
remove an N glycosylation site, a possible adaptation to mask an antigenic site (Fig. 2). The 8 
escape mutants selected in presence of the bivalent Nb presented not only the K189E/N 9 
mutation, but an additional D145N mutation located in the stalk of HA, 40 residues 10 
upstream of the membrane anchor. The results of the hemaglutination assays and 11 
microneutralization experiments suggest that mutation K189N/E is necessary and sufficient 12 
to abolish binding to the Nb in a monovalent or bivalent conformation, indicating a close 13 
proximity between the antigenic B site and the receptor binding domain. Those results are 14 
the first one reported of the potential antiviral activity of a Nb against the  influenza virus.  15 
 16 
Fig. 2. Ribbon representation of the H5N1 HA trimeric protein. Two mutations in the head 17 
of the trimer confer resistance to the monovalent and bivalent VHH C-8. The mutation 18 
K189N/E was necessary and sufficient to prevent binding of both mono and bivalent 19 
proteins. (PDB : 2IBX) 20 
The Nb viral neutralization activity against a trimeric HA molecule (HA) was greatly 21 
enhanced when presented as bivalent and trimeric molecule, but the dynamics and details 22 
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of the binding are not clear. It has been demonstrated that during intramolecular binding, a 1 
multivalent molecule has greater avidity than its monovalent counterpart. But a very 2 
interesting question is whether intermolecular binding occurs during Nb binding to the HA. 3 
In recent reports, the existence of intermolecular binding was proved to enhance an antiviral 4 
effect (Wang & Yang, 2010). Intermolecular binding could explain the increase in the 5 
neutralization activity:  steric, the hindrance of the HA for its cellular receptor is enhanced, 6 
and the flexibility of the HA is decreased.  7 
3. RSV virus 8 
Respiratory Syncytial Virus (RSV) infections are the leading cause of acute lower respiratory 9 
tract infections (ALRI) in children and associated hospitalizations world wide (Falsey et al., 10 
2005; Nair et al., 2010). There is no specific antiviral therapy for RSV infection available. Each 11 
year 66, 000 – 199,000 children die worldwide due to RSV ALRI. Most pediatric cases of fatal 12 
RSV infections occur in developing countries. As RSV infections do not evoke protective 13 
immunity, infections occur throughout life, causing severe morbidity in young infants, the 14 
elderly, and immune-comprised adults (Boyce et al., 2000; Falsey et al., 2005).  15 
Although high levels of RSV neutralizing antibodies correlate with lower frequencies of 16 
RSV-associated ALRI, no RSV vaccine is available (Glezen et al., 1981). However, monthly 17 
administration of large amounts of a humanized RSV neutralizing antibody, palivizumab 18 
(Synagis), reduces RSV-associated hospitalization of high risk infants by about 78-39% 19 
(Groothuis & Simoes, 1993). Palivizumab is currently the sole monoclonal antibody that is 20 
approved for preventing viral infection. Palivizumab blocks fusion of the RSV membrane 21 
with the membrane of the target cell by binding to the RSV fusion protein (F) (Huang et al., 22 
2010). However, due to the high cost of palivizumab, there is an urgent need for new anti-23 
virals that can prevent or treat RSV infections. RSV neutralizing have been developed as an 24 
alternative to existing antibodies (Hultberg et al., 2011). 25 
3.1 RSV binding VHHs antiviral effect: comparison with Synagis Mab. 26 
To investigate if Nbs could be used for antiviral therapy, Nbs that bind to the palivizumab 27 
epitope were developed. For this purpose, two llamas were immunized with recombinant 28 
RSV A F protein (RSV FTM-) lacking the transmembrane region (Hultberg et al., 2011). This 29 
protein folds into trimers that resemble the native RSV F protein in its post-fusion 30 
conformation (Ruiz-Arguello et al., 2004). Remarkably, RSV FTM- proteins can be readily 31 
recognized by RSV F neutralizing antibodies that, just like palivizumab, bind to the 32 
antigenic site II (McLellan et al., 2011; Swanson et al., 2011). In this way, RSV FTM- 33 
immunization can potentially induce RSV F antigenic site II specific camelid HCAbs. HCAbs 34 
that specifically bind to the RSV F antigenic region II were enriched by biopanning using 35 
RSV FTM- protein and competitive elution in the presence of excess of palivizumab antibody. 36 
From these HCAbs, VHHs (or Nbs) were produced and tested for binding to the RSV FTM- 37 
protein. Twelve VHHs that bound to the RSV F protein were tested for neutralization of 38 
RSV Long strain (RSV A subtype) virus in a micro-neutralization assay. Two VHHs (RSV-C4 39 
and the RSV-D3) could neutralize RSV in the high nanomolar range (IC50: 640 nM and 300 40 
nM, respectively), which is similar to the neutralization activity than the Synagis Fab (IC50: 41 
549.2 nM) and about 100-fold less effective as the Synagis Mab (IC50: 3.02 nM). However, in 42 
contrast to palivizumab, neither RSV-C4 nor RSV-D3 VHHs could neutralize RSV B subtype 43 
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virus in vitro. On the contrary, another VHH (RSV-E4) could neutralize RSV B infection to 1 
some extent.  2 
The epitopes of different VHHs were determined by antibody competition assays and 3 
diverse antibody escape RSV mutants.  Whereas RSV-C4 and RSV-D3 VHHs readily 4 
competed with palivizumab for binding to recombinant RSV FTM- or inactivated RSV 5 
virions, RSV-E4 competed with 101 Fab, which is known to bind to the antigenic region IV-6 
VI (Wu et al., 2007). These data are in line with the observation that AA substitutions within 7 
antigenic regions II and IV-VI, respectively, affected the binding of both RSV-D4 and RSV-8 
C3 VHHs and RSV-E4 VHH. These data strongly suggest that both RSV-C3 and RSV-D4 9 
bind to antigenic region II (palivizumab epitope) (Crowe et al., 1998) whereas RSV-E4 VHH 10 
binds to antigenic region IV-VI, explaining the observed differences in neutralization.  11 
The affinity of the three VHHs, Synagis Mab and Synagis Fab was determined by Surface 12 
Plasmon Resonance using recombinant RSV F TM- as bait. The KD of RSV-D3, RSV-E4 and 13 
RSV-E4 were in the low nanomolar range: 9.24 nM, 1.78 nM and 0.45 nM, respectively. 14 
Although RSV-D3 was more effective than RSV-C4 at neutralizing RSV A, it had a lower 15 
affinity for FTM- than RSV-C4.  Moreover, the efficient binding of RSV-E4 VHH to a 16 
neutralizing epitope (antigenic region IV-VI) was not associated with neutralization of RSV 17 
A. This suggests that the affinity of VHHs for the recombinant RSV FTM-, which likely 18 
represents the F protein in its post-fusion conformation, does not correlate directly with 19 
neutralization of living RSV (Table 1.) 20 
 21 
*Obtained from two different cell based assays, microneutralization and plaque assay 22 
Table 1. Inhibition and protection of the RSV virus A binding RSV-D3 23 
The avidity of a binding molecule can be increased by using a multivalent format (Rudge et 24 
al., 2007; Wang & Yang, 2010). To increase the antiviral potential of RSV-D3 we formatted it 25 
into a bivalent molecule, by using a flexible linker, Gly4/Ser (GS). Surprisingly, bivalent 26 
RSV-D3 VHHs with GC linkers of different sizes neutralized RSV A Long virus between 27 
2421 and 4181 times more efficient than monovalent RSV-D3 VHHs, reaching picomolar 28 
range (IC50: 190-110 pM). In contrast, Synagis Mab was only 200 times more efficient in 29 
 
Antiviral Drugs 
 
10
neutralizing RSV A virus (IC50: 6.5 nM) than its corresponding Fab fragment. In this way, 1 
bivalent RSV F specific VHHs outperform the Synagis antibody in RSV neutralization. 2 
Moreover, in contrast to its monovalent format, bivalent RSV-D3 could also neutralize RSV 3 
B1 strain virus. Also, neutralization was notably boosted against RSV A and B virus 4 
subtypes by linking two different VHHs (RSV-D3 and RSV-E4) which target different 5 
epitopes. The enhancement of the activity by linking two VHHs is likely due the flexibility 6 
of the linker. Experiments aiming to characterize the binding dynamics of the RSV-D3 to the 7 
F protein are necessary for characterizing intra- or intermolecular binding. 8 
The RSV F is responsible of fusion of the viral lipid membrane with the host membrane, but 9 
also participates in attachment of the RSV virions to target cells. Moreover, it was recently 10 
demonstrated that RSV F protein can bind to nucleolin expressed at the surface of target 11 
cells, and that this interaction is crucial for RSV infection in vitro and in vivo (Tayyari et al., 12 
2011). After viral attachment, the RSV F protein mediates fusion of the viral membrane with 13 
the plasma membrane of the target cell, thereby releasing the viral genome into the 14 
cytoplasm of the host cell. This process involves a series of conformational changes in the F 15 
protein from a metastable pre-fusion to a stable post-fusion conformation. We recently 16 
demonstrated that bivalent RSV-D3 VHHs can prevent RSV infection both before and after 17 
viral attachment and can inhibit syncytia formation, but cannot hamper RSV attachment 18 
(Schepens et al., 2011). Together, these observations constantly indicate that, in a similar 19 
mechanism that palivizumab, bivalent RSV-D3 VHHs prevent RSV infection by blocking 20 
fusion. Although the conformations of the RSV F antigenic regions II and IV-VI are 21 
maintained in the post-fusion form, it is more plausible that the RSV VHHs block viral 22 
fusion and syncytia formation by binding to the RSV F protein in either its pre-fusion or 23 
intermediate conformations (Fig. 3). Possibly, binding of the VHHs to the antigenic region II 24 
interferes with the conformational changes of the F protein that are required for fusion. 25 
Immune compromised Balb/c mice (cyclophosphamide treatment) were used to test 26 
whether bivalent RSV-D3 VHHs can protect against RSV infection in vivo (Schepens et al., 27 
2011). As VHHs are known to remain active in the respiratory tract after nebulisation, 28 
bivalent RSV-D3 and control VHHs were administered intranasally (patent application WO 29 
2009/147248). Prophylactic treatment of mice with 5 mg/kg bivalent RSV-D3 VHH or 30 
palivizumab reduced RSV pulmonary titers below the detection limit of the RSV plaque 31 
assay. This strong reduction was confirmed by qPCR analysis. Remarkably, as low as 0.6 32 
mg/kg bivalent RSV-D3 could prevent or strongly reduce (at least 100-fold) pulmonary RSV 33 
replication. In comparison, monovalent RSV-D3 VHH protected against pulmonary RSV 34 
replication about 25 times less efficiently than its bivalent counterpart. For prophylactic 35 
treatment to be valuable, even if is easy to administer, its effect should be long lasting. We 36 
demonstrate that intranasal administration of bivalent RSV-D3 VHHs can protect against 37 
RSV infection for at least for 48 hours. Prophylactic treatment with palivizumab in high risk 38 
infants reduces RSV associated hospitalization, but no effective therapeutic is available. 39 
Therefore, RSV-D3 VHHs were also evaluated as therapeutic treatments. Intranasal 40 
administration of RSV-D3 VHHs 4 or 24 hours after infection strongly reduced pulmonary 41 
RSV replication (at least 100-fold). Plaque assays also indicated that administration of 42 
bivalent RSV-D3 VHHs 72 hours after RSV treatment can reduce pulmonary RSV 43 
replication. However, the lung homogenates used to quantify the pulmonary RSV titer in 44 
mice were treated 72 hours after infection and still contained neutralizing RSV VHHs. 45 
Therefore, it is not clear to which extend treatment at this time point reduced RSV 46 
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replication in vivo. The potential of bivalent VHHs for preventing morbidity and pulmonary 1 
inflammation upon RSV infection was assessed in a non immunocompromised mice model. 2 
Prophylactic administration of bivalent RSV-D3 VHHs (1 mg/kg) completely prevented 3 
body weight loss and pulmonary cell infiltration that was observed in mice treated with 4 
control VHHs. Therapeutic treatment with bivalent RSV-D3 VHHs 24 h after infection 5 
partially reduced body weight loss and pulmonary cell infiltration. These observations 6 
confirm the in vivo antiviral potential of neutralizing VHHs.  7 
 8 
Fig. 3. Ribbon representation of the structure of the RSV F protein trimer in its post-fusion 9 
form. The head and stalk of this recombinant protein are depicted, lacking the fusion 10 
peptide, transmembrane region and cytoplasmic domain. The immunogenic epitopes 11 
recognized by Mab 101F (site II) and palimuzab (site IV-VI) are in red and blue, respectively, 12 
and the rest of the F protein is in green. The RSV-D3 and RSV-C4 resistant escape mutants 13 
are shown in yellow. Mutations I432T, K433T and S436F in site II disrupt the binding of the 14 
RSV-C4. The K262Y, N268I and K272E in the site IV-IV result in loss of binding of the RSV-15 
D3 molecule. (PDB: 3RKI). 16 
Currently Ablynx is preparing a phase I clinical trial to evaluate the safety of a trivalent RSV 17 
neutralizing VHH format consisting of three identical VHHs. Preclinical evaluation of this 18 
lead candidate can readily neutralize a broad spectrum of clinical RSV A and RSV B subtype 19 
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viruses more efficiently than Synagis (abstract, 7th international RSV symposium). In vivo 1 
studies demonstrated that both prophylactic and therapeutic treatment with this RSV 2 
neutralizing VHH can readily reduce RSV replication in the upper and lower respiratory 3 
tract of cotton rats (abstract, 7th international RSV symposium).  4 
In summary, neutralizing RSV VHHs are promising new candidates as anti-RSV 5 
therapeutics for different reasons. First, VHHs allow versatile formatting including the 6 
creation of multivalent formats by the use of flexible linkers. This feature enabled the 7 
creation of bivalent and trivalent VHH which can neutralize RSV at picomolar range, more 8 
than 1000-fold more efficient than their monovalent counterpart. Second, by linking two 9 
different VHHs which neutralize different virus strains (such as the RSV A versus the RSV B 10 
subtype strains) cross-reactive VHH constructs can be obtained. Moreover, as a result of 11 
avidity effects, cross linking VHH with different specificity can considerably improve the 12 
neutralizing activity. Third, the VHHs small size and protruding paratopes can contribute to 13 
its neutralization activity. As structural models and electron microscopic analysis indicate 14 
that the antigenic region II is located at the side of the RSV F protein trimer, at the dense 15 
surface of RSV virions this region is reasonably more accessible for small and flexible VHH 16 
formats rather than for large more rigid antibodies (McLellan et al., 2011; Ruiz-Arguello et 17 
al., 2004) (Fig. 3). Fourth, due to their high stability at stringent conditions, VHHs can be 18 
administered via nebulisation, which allows a rapid accumulation of high amounts of 19 
neutralizing VHH at the site of respiratory viral infections. In addition, due to the high 20 
stability of VHHs and the ease of intranasal or pulmonary administration, VHH therapy 21 
could be applied more generally, even in developing countries. 22 
4. Rabies virus 23 
Rabies virus (RV) is a single stranded RNA virus of the Rhabdoviridae family, genus 24 
Lyssavirus. Infection with RV in humans causes acute encephalitis, with a mortality rate of 25 
almost 100%. It is transmitted to humans by bites from a carnivore or a quiroptera vector 26 
and most cases occur in Asia or Africa. The long incubation period following infection by 27 
RV presents a paradox, because of the absence or very weak immune response (Johnson et 28 
al., 2010). The small amount of virus inoculated after infection and the neurotropism of RV 29 
are believed to contribute to the absence of effective antibodies in the patient. After the bite, 30 
wound cleaning can reduce the chances of a productive infection in humans. Passive 31 
immunization and vaccination promptly after exposure is the only effective therapeutic tool 32 
available now. Modern vaccines are inactivated virus produced from continuous cell lines, 33 
like the vaccine by Aventis Pasteur (human diploid cells). Nevertheless, in underdeveloped 34 
countries, the established RV therapy (attenuated virus, Mab anti RV) is too expensive for 35 
most of the population. RV has a genome of 12 kDa coding for 5 proteins: nucleoprotein, 36 
phosphoprotein, matrix, RNA-dependent RNA polymerase and the Glycoprotein (RVG). In 37 
the virus particle, the RVG is the only viral protein exposed as a trimeric spike, and it is 38 
responsible for recognition of cellular receptors, virulence and antigenicity.  39 
4.1 Nbs present a broad protection against Rabies virus 40 
For more than 25 years, two well-defined antigenic sites in the RVG have been characterized 41 
by Mabs: antigenic sites II and III (Lafon et al., 1990). Other epitopes have also been 42 
characterized, but their contribution to antigenicity is minor. Antigenic site III extends from 43 
 
Single Domain Camelid Antibodies that Neutralize Negative Strand Viruses 
 
13 
330 to 340 amino acids and is linear (Seif et al., 1985). Mutations in this site affect virulence 1 
and the host range of the virus. On the contrary, antigenic site II is conformational and 2 
discontinuous and is determined by two regions, amino acids 34-42 and 198-200. Site II is 3 
responsible for about 70 % of the known Mabs against RVG (Benmansour et al., 1991). 4 
RGV is an interesting target for the VHH platform because alternative cost effective 5 
antirabies tools are needed. By using an approach similar to those previously discussed for  6 
influenza and RSV, a llama was immunized with recombinant RVG and five VHHs were 7 
obtained (Rab – E8, H7, F8, E6 and C12). The neutralizing activity of those VHHs was 8 
validated against 10 Rabies genotype 1 viruses: 3 laboratory strains (CVS-11 as prototype, 9 
ERA, CB-1) and 7 field isolates and one rabies genotype 5 virus (EBL-V1) was included to 10 
validate broad cross neutralization. A cell based assay was used, the Rapid Fluorescent 11 
Focus Inhibition Test (RFFIT) (Vene et al., 1998). This assay has been internationally 12 
recognized as the in vitro standard for testing virus neutralizing antibodies. Mab 8-32, which 13 
recognizes antigenic site II of RVG was also included as positive control (Montano-Hirose et 14 
al., 1993). VHHs F8, E6, H7 and C12 neutralized the genotype 1 strains: CB-1 and ERA with 15 
an IC50 in the low nanomolar range and the CVS-11 strain in the low to high nanomolar 16 
range. They could also neutralize several RV field isolates. On the other hand, E8 efficiently 17 
neutralized only CB-1 and CVS-11, in the low and high nanomolar range, respectively. C12 18 
and E6 had better neutralization activity than Mab 8-2 against the ERA and CB-1 strains. 19 
Using the same reasoning, the authors also used the bivalent approach against the Rabies 20 
genotype 1 CVS -11 and the genotype 5 EBLV-1. Bivalent monoparatopic VHHs were 21 
constructed using a Gly4/Ser linker, using the 12, H7, E8 and F8 VHHs. The neutralization 22 
IC50 of these constructions was reduced from a two-fold to 180-fold relative to the 23 
monovalent protein, indicating enhancement of the neutralization. Nevertheless, the best 24 
results were obtained when biparatopic molecules were used. The E6/H7 and the H7/F8 25 
molecules increased the neutralization potency by a 2 log factor, while the E8/H7 increased 26 
3 log-fold, compared with the monovalents. E8/H7 even outperformed Mab 8 -2 against the 27 
CVS-11. On the contrary, in the case of the genotype 5 strain EBLV-1, the monovalent 28 
molecules showed modest neutralization or non at all. The enhanced neutralization of 29 
biparatopic molecules was confirmed by E8/C12, which presented an increase in the 30 
neutralization potential of 147-fold (IC50 = 3.76 nM) relative to the monovalent moiety, but 31 
not as low as Mab 8 – 2 (IC50 = 0.12 nM). The results of competition assays of the 5 VHHs 32 
against the Mab 8- 2 showed that E6, E8, F8 and H7 compete for the same epitope. On the 33 
other hand, C12 did not compete which indicates that it recognizes a different epitope. The 34 
difference in epitope recognition could be one of the causes of the strong and broad effect of 35 
biparatopic molecules, especially for E8/C12. Experiments using VHHs against Rabies 36 
mutant virus, carrying substitutions in the known residues in the antigenic site II could 37 
localize the exact binding sites of these new antibodies. For example, it has been reported 38 
that substitution K198E of the glycoprotein abolish the binding of the Mab 8–2 (Montano-39 
Hirose et al., 1993). Unfortunately, the crystallographic structure of the RVG protein has not 40 
been reported. The use of vesicular stomatitis virus glycoprotein is accepted as a modeling 41 
reference and as a surrogate template for RVG structure (Cibulski et al., 2009; Tomar et al., 42 
2010). We used the alignment of this protein with the RVG as reference to show the possible 43 
structure of antigenic site II (Fig. 4). The purpose of this estimate is to show the tendency of 44 
the VHHs to recognize conformational rather than linear epitopes. In line with the results of 45 
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the neutralizing VHHs against  influenza and RSV, the results of the broadness and the 1 
strong potency against both RV genotypes indicate the RV neutralizing VHHs as a 2 
promising tool. Nevertheless, in contrast with the previous cases of the  influenza and RSV 3 
VHHs, there is not in vivo validation of the RV neutralizing VHHs available. 4 
 5 
Fig. 4. Schematic representation of the vesicular stomatitis virus protein G trimer. This 6 
protein is taken as reference to depict the amino acids corresponding to the antigenic site II 7 
of the Rabies Virus glycoprotein (residues 34-42, and 198-200, in blue). The localization of 8 
the K198E mutation that prevents the binding of the Mab 8-2 is shown in red. The VHHs E8, 9 
F8, E6 and H7 compete with the Mab 8- 2 for the binding, which means that their epitopes 10 
might be within antigenic site II. (PDB: 2CMZ). 11 
5. Conclusion  12 
The Nb platform is a new and promising antiviral tool. The ease of producing  in bacterial 13 
and lower eukaryotic cells and the possibility of producing tailor-made constructions makes 14 
them an attractive and cost effective alternative to established antiviral means. This 15 
approach may be useful for the treatment of infectious orphan diseases (including viral) and 16 
in developing countries, where the “standard” prophylaxis or therapy is prohibitively 17 
expensive or not available. In this work we have discussed findings on recently developed  18 
directed against three viruses affecting humans:  the generation and in vitro validation of the 19 
Nbs or VHHs against  influenza H5N1, RSV and RV (Hultberg et al., 2011); as well as the in 20 
vivo validation of the  influenza HA binding VHH (Ibañez et al., 2011) and RSV (Schepens et 21 
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al., 2011). In the case of protection against  influenza infection the bivalent format of the 1 
proved superior in vitro and in vivo.  But, as indicated by the successful in vivo validation of 2 
one of the H5N1 strains, it is imperative to extend this validation to other  influenza strains. 3 
Furthermore, it would be worthwhile to isolate and characterize that recognize conserved 4 
domains in HA, such as the stalk. In line with the  influenza results, the activity of RSV and 5 
RVG neutralizing was significantly higher for the bivalent than the monovalent format: both 6 
the cross neutralization activity and potency were higher. Those results manifest the 7 
advantages of using a multimeric format against multimeric viral targets. The enhanced 8 
antiviral potential of the multimeric format could be due to increased avidity and/or the 9 
intra or inter molecular binding could contribute in the enhancement. Experiments to assess 10 
the binding mechanism could lead to further improvements. The results overall confirm two 11 
important points: the high potential of the Nbs as prophylactic and therapeutic tools, and 12 
the possibility of using Nbs directed against other infectious diseases. There is limited 13 
function and sequence similarity among the three proteins used as antigens (HA, RSVF and 14 
RVG) other than their trimeric architecture and antigenicity. Nevertheless, the HA and the 15 
RVG are functionally similar and both are involved in the cellular receptor binding, whereas 16 
RSVF participates also in virion receptor binding, it s main function is in membrane fusion. 17 
In all three cases, showed capacity to neutralize the viral target by blocking binding or 18 
hampering necessary conformational changes, indicating the great versatility and efficiency 19 
of the antiviral discussed here.  In competition assays, the recognition of non conventional 20 
epitopes by these antiviral was not observed, but could be focused on in the future. Nbs 21 
recognized well known antigenic sites that are also targeted by Mabs. The HA, RSV F and 22 
RVG are not enzymes, and lack extensive antigenic clefts. This could be one reason why Nbs 23 
showed preference for recognition of “classical” epitopes in these viral proteins. If the 24 
presence of antigenic clefts could lead to recognition of non “classical” epitopes in the viral 25 
proteins, targeting viral enzymes could be an interesting approach. Enzymes such as the  26 
influenza Neuraminidase are potential targets. This viral sialidase presents a catalytic cleft, 27 
in which the framework and substrate contact residues are conserved in most of the  28 
influenza strains. The coming years will probably bring potent novel anti-viral directed 29 
against different viruses and it is likely that some of these Nbs will reach clinical trials.  30 
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